Breaking News, Financial News

Financial Report: Gilead Sciences 2Q

Product sales were up 29% to a record $1.6 billion, driven primarily by the antiviral franchise with product sales up 26% to $1.4 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 2Q 2Q Revenues: $1.7 billion (+29%) 2Q Earnings: $571.4 million (+31%) YTD Revenues:$3.2 billion (+28%) YTD Earnings: $1.2 billion(+26%) Comments: Product sales were up 29% to a record $1.6 billion, driven primarily by the antiviral franchise with product sales up 26% to $1.4 billion. Truvada sales were up 18% to $608.1 million. Atripla sales were up 60% to $569.1 million. Other antiviral product sales, including Viread, Hepsera and Emtriva, were down 6% to $233.1 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters